Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
AuthorsMitchell, Christopher D
Richards, Susan M
Kinsey, Sally E
Lilleyman, John S
Vora, Ajay J
Eden, Tim O B
AffiliationPaediatric Haematology/Oncology, John Radcliffe Hospital, Oxford, UK. email@example.com
MetadataShow full item record
AbstractCorticosteroids are an essential component of treatment for acute lymphoblastic leukaemia (ALL). Prednisolone is the most commonly used steroid, particularly in the maintenance phase of therapy. There is increasing evidence that, even in equipotent dosage for glucocorticoid effect, dexamethasone has enhanced lymphoblast cytotoxicity and penetration of the central nervous system (CNS) compared with prednisolone. Substitution of dexamethasone for prednisolone in the treatment of ALL might, therefore, result in improved event-free and overall survival. Children with newly diagnosed ALL were randomly assigned to receive either dexamethasone or prednisolone in the induction, consolidation (all received dexamethasone in intensification) and continuation phases of treatment. Among 1603 eligible randomized patients, those receiving dexamethasone had half the risk of isolated CNS relapse (P = 0.0007). Event-free survival was significantly improved with dexamethasone (84.2% vs. 75.6% at 5 years; P = 0.01), with no evidence of differing effects in any subgroup of patients. The use of 6.5 mg/m(2) dexamethasone throughout treatment for ALL led to a significant decrease in the risk of relapse for all risk-groups of patients and, despite the increased toxicity, should now be regarded as part of standard therapy for childhood ALL.
CitationBenefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. 2005, 129 (6):734-45 Br. J. Haematol.
JournalBritish Journal of Haematology
- Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
- Authors: Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ
- Issue date: 2008 Jun
- No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.
- Authors: Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, Kamijo T, Isoyama K, Kajiwara M, Sotomatsu M, Sugita K, Sugita K, Maeda M, Yabe H, Kinoshita A, Kaneko T, Hayashi Y, Ikuta K, Hanada R, Tsuchida M
- Issue date: 2005 Sep 20
- Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia?
- Authors: Zheng C, Liu X, Wu J, Cai X, Zhu W, Sun Z
- Issue date: 2010 Oct
- Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
- Authors: Manabe A, Ohara A, Hasegawa D, Koh K, Saito T, Kiyokawa N, Kikuchi A, Takahashi H, Ikuta K, Hayashi Y, Hanada R, Tsuchida M, Tokyo Children's Cancer Study Group
- Issue date: 2008 Aug
- Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
- Authors: Tolar J, Bostrom BC, La MK, Sather HN
- Issue date: 2005 Jul